🎉 M&A multiples are live!
Check it out!

Quince Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Quince Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Quince Therapeutics Overview

About Quince Therapeutics

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.


Founded

2012

HQ

United States of America
Employees

36

Website

quincetx.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$18.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Quince Therapeutics Financials

Quince Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Quince Therapeutics achieved revenue of n/a and an EBITDA of -$36.0M.

Quince Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Quince Therapeutics valuation multiples based on analyst estimates

Quince Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$26.8M -$36.0M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$51.7M -$31.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Quince Therapeutics Stock Performance

As of April 15, 2025, Quince Therapeutics's stock price is $1.

Quince Therapeutics has current market cap of $44.9M, and EV of $18.9M.

See Quince Therapeutics trading valuation data

Quince Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$18.9M $44.9M XXX XXX XXX XXX $-1.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Quince Therapeutics Valuation Multiples

As of April 15, 2025, Quince Therapeutics has market cap of $44.9M and EV of $18.9M.

Quince Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Quince Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Quince Therapeutics and 10K+ public comps

Quince Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $18.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.5x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Quince Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Quince Therapeutics Valuation Multiples

Quince Therapeutics's NTM/LTM revenue growth is n/a

Quince Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Quince Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Quince Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Quince Therapeutics and other 10K+ public comps

Quince Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 34% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Quince Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Quince Therapeutics M&A and Investment Activity

Quince Therapeutics acquired  XXX companies to date.

Last acquisition by Quince Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Quince Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Quince Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Quince Therapeutics

When was Quince Therapeutics founded? Quince Therapeutics was founded in 2012.
Where is Quince Therapeutics headquartered? Quince Therapeutics is headquartered in United States of America.
How many employees does Quince Therapeutics have? As of today, Quince Therapeutics has 36 employees.
Who is the CEO of Quince Therapeutics? Quince Therapeutics's CEO is Mr. Dirk Thye, M.D..
Is Quince Therapeutics publicy listed? Yes, Quince Therapeutics is a public company listed on NAS.
What is the stock symbol of Quince Therapeutics? Quince Therapeutics trades under QNCX ticker.
When did Quince Therapeutics go public? Quince Therapeutics went public in 2019.
Who are competitors of Quince Therapeutics? Similar companies to Quince Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Quince Therapeutics? Quince Therapeutics's current market cap is $44.9M
Is Quince Therapeutics profitable? Yes, Quince Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.